Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalotuzumab - Merck & Co

Next Previous
X
Search
Drug Profile

Dalotuzumab - Merck & Co

Alternative Names: Anti-IGF-1 receptor monoclonal antibody - Pierre Fabre; Anti-IGF-1R monoclonal antibody - Pierre Fabre; F 50 035; h7C10; MK-0646

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pierre Fabre
  • Developer M. D. Anderson Cancer Center; Merck & Co
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action IGF type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Multiple myeloma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 22 Apr 2021 Discontinued - Phase-I for Breast cancer (First-line therapy) in USA, European Union, South Korea, Israel, Brazil (IV) before April 2021 (Merck & Co's pipeline, April 2021) (Pieree Fabre's pipeline, April 2021)
  • 22 Apr 2021 Discontinued - Phase-II for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, Denmark, France, Germany, Italy, Spain, Sweden, United Kingdom, Canada, Colombia, Israel, South Korea, Peru, Taiwan, USA, Brazil, Japan, Czech Republic, Portugal (IV) before April 2021 (Merck & Co's pipeline, April 2021) (Pieree Fabre's pipeline, April 2021)
  • 22 Apr 2021 Discontinued - Phase-II for Colorectal cancer (Combination therapy, Metastatic disease) in Germany, Italy, South Korea, Peru, Taiwan, USA (IV) before April 2021 (Merck & Co's pipeline, April 2021) (Pieree Fabre's pipeline, April 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top